Sonoma Pharmaceuticals Reports 2026 Annual Meeting Vote Results

What Happened

• Sonoma Pharmaceuticals, Inc. (SNOA) filed an 8-K reporting the results of its annual meeting held on September 16, 2026. Proxies were solicited pursuant to the company’s definitive proxy statement filed July 28, 2026.
• A total of 4,788,425 shares of common stock were entitled to vote; 2,082,799 shares (about 43.5% of outstanding) were present or represented by valid proxy. Each common share carried one vote.

Key Details

• Election of Class III Director: Jerry McLaughlin was elected. Vote tally — For: 336,722; Withheld: 20,198.
• Advisory vote on executive compensation (non-binding): Approved. For: 286,312; Against: 38,559; Abstain: 32,049.
• Ratification of independent registered public accounting firm: Frazier & Deeter, LLC was ratified. For: 2,063,173; Against: 12,522; Abstain: 7,104.
• Approval to adjourn the meeting to solicit additional proxies if needed: For: 1,797,076; Against: 119,486; Abstain: 166,237.

Why It Matters

• The election and ratification outcomes confirm the board composition and continuation of Frazier & Deeter, LLC as Sonoma’s auditor for the fiscal year ending March 31, 2027 — both are governance items investors watch for continuity and oversight.
• The advisory “say-on-pay” was approved (non-binding), indicating majority shareholder support for the company’s disclosed executive compensation for the year ended March 31, 2026.
• Vote totals varied by proposal (reflecting different participation/choices on each item); the meeting had a quorum with roughly 43.5% of shares represented.